Luminex Corporation LMNX reported first-quarter 2016 adjusted earnings (including stock-based compensation) of 27 cents per share, which comfortably surpassed the Zacks Consensus Estimate of 13 cents.
Adjusted earnings surged 36.5% on a year-over-year basis driven by strong top-line growth and operating margin expansion.
Revenues increased 9.1% year over year to almost $63 million, which was slightly better than the Zacks Consensus Estimate of $61 million. The year-over-year improvement may be attributed to better system sales and a stellar performance by the company's assay product portfolio.
Adjusted gross margin expanded 150 basis points (bps) on a year-over-year basis to 71.1%, driven by favorable product mix.
Research & development (R&D) expenses, as a percentage of revenues, declined 10 basis points (bps) to 17.5%. Selling, general and administrative (SG&A) expenses decreased 140 bps to 32.3% in the reported quarter.
Adjusted operating margin expanded 320 bps on a year-over-year basis to 22.4%, driven by higher revenues as well as stringent cost control.
System sales jumped 39.5% on a year-over-year basis to $8.3 million. Royalty revenues increased 7.2% on a year-over-year basis to $11.5 million.
Consumables sales soared 19.7% to $11.9 million. Luminex's partner revenues grew 18% year over year, far ahead of its annual growth target range of 6% to 9%, primarily driven by robust demand for the company's products in the life science markets.
Assay revenues increased 6.3% to $27 million, reflecting the successful execution of the company's molecular diagnostic strategy. Infectious disease assay sales comprised approximately 72% of the total assay sales in the quarter, with genetic testing assays representing 28%.
Molecular diagnostic business generated approximately $28 million in revenues driven by 20% growth in Luminex's infectious disease test portfolio.
In the reported quarter, Luminex sold 255 multiplexing analyzers.
Luminex now expects full-year 2016 revenues in the range of $247--$255 million, up from the previous range of $245-$255 million. Second-quarter 2016 revenues are expected between $60 million and $62 million.
Luminex expects consumables revenues to increase in the mid-single digit range for 2016. Royalties are expected to grow in the low single-digits range.
Management at Luminex expects assay revenue growth in the mid single-digits range in 2016. The company assumes that LabCorp CF will remain its customer throughout 2016.
Luminex continues to expect a couple of million dollar contribution from ARIES in 2016.
Zacks Rank & Key Picks
Currently, Luminex carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical space are Edwards Lifesciences EW , IRadimed Corporation IRMD and Abiomed ABMD . While Edwards Lifesciences and IRadimed sport a Zacks Rank #1 (Strong Buy), Abiomed carries a Zacks Rank #2 (Buy).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.